Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which has branded Cymerus.
|14 Jan 2022||$0.57||$-0.03||-5.00%||38,747||$0.60||$0.60||$0.57|
|13 Jan 2022||$0.60||$0.05||9.09%||277,044||$0.59||$0.60||$0.58|
|12 Jan 2022||$0.55||$-0.03||-5.17%||16,327||$0.58||$0.58||$0.55|
|11 Jan 2022||$0.58||$0.02||3.54%||59,305||$0.57||$0.58||$0.57|
|10 Jan 2022||$0.57||$0.01||1.82%||87,702||$0.55||$0.57||$0.55|
|07 Jan 2022||$0.55||$-0.02||-3.48%||47,900||$0.58||$0.58||$0.55|
|06 Jan 2022||$0.58||$-0.02||-3.39%||48,654||$0.56||$0.58||$0.56|
|05 Jan 2022||$0.59||$0.00||0.00%||131,780||$0.59||$0.59||$0.56|
|04 Jan 2022||$0.59||$0.04||7.34%||305,020||$0.55||$0.59||$0.55|
|31 Dec 2021||$0.55||$0.04||7.84%||116,132||$0.53||$0.55||$0.53|
|30 Dec 2021||$0.51||$0.01||2.00%||69,552||$0.52||$0.52||$0.50|
|29 Dec 2021||$0.50||$0.02||4.17%||199,507||$0.49||$0.53||$0.48|
|24 Dec 2021||$0.48||$0.00||0.00%||11,873||$0.48||$0.48||$0.48|
|23 Dec 2021||$0.48||$0.01||2.13%||40,942||$0.47||$0.48||$0.47|
|22 Dec 2021||$0.47||$0.02||4.44%||54,113||$0.48||$0.48||$0.47|
|21 Dec 2021||$0.45||$-0.01||-2.17%||103,856||$0.46||$0.46||$0.45|
|20 Dec 2021||$0.46||$-0.02||-4.21%||69,857||$0.46||$0.47||$0.46|
|17 Dec 2021||$0.48||$0.02||4.35%||19,851||$0.46||$0.48||$0.46|
|02 Dec 2021||Stewart Washer||Buy||60||$30,563||
|30 Nov 2021||Geoffrey Brooke||Buy||40||$21,044||
|Dr Paul K Wotton||Non-Executive Director||Jun 2016||
Dr Wotton is the Chief Executive Officer of Obsidian Therapeutics, a leading synthetic biology company based in Cambridge, Massachusetts. Prior to this, he was the Founding President and CEO of Sigilon Inc. He was previously President and CEO of Ocata Therapeutics Inc. (NASDAQ: OCAT) guiding the company through a take-over by Astellas Pharma Inc., in a US$379 million all cash transaction. Prior to Ocata, Dr Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS) since October 2008. Prior to joining Antares, Dr Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Dr Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr Wotton is a member of the Board and Governance Committee of Vericel Corporation, a US company developing autologous cellular therapies and a member of the board at PaxMedica where he is Chairman of the Compensation Committee. He was a member of the board of Veloxis Pharmaceuticals A/S and Chairman of the Compensation Committee, until its acquisition by Asahi Kasai in February 2020 in a $1.3 billion all cash transaction. He is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. Dr Wotton received his PhD in pharmaceutical sciences from the University of Nottingham. In 2014, he was named New Jersey EY Entrepreneur of the Year in Life Sciences.
|Dr Ross Macdonald||Chief Executive OfficerManaging Director||Aug 2013||
Dr Macdonald has over 34 years' experience and a track record of success in pharmaceutical and biotechnology businesses. His career history includes positions as Vice President of Business Development for Sinclair Pharmaceuticals Ltd (now Sinclair Pharma Ltd), a UK-based specialty pharmaceuticals company and Vice President, Corporate Development for Stiefel Laboratories Inc, then the largest independent dermatology company in the world and acquired by GlaxoSmithKline in 2009 for Euros 2.25b. Dr Macdonald has also served as CEO of Living Cell Technologies Ltd, Vice President of Business Development of Connetics Corporation and Vice President of Research and Development of F H Faulding & Co Ltd. Dr Macdonald currently serves as a member of the Investment Committee of UniSeed Management Pty Ltd.
|Mr Peter Webse||Company Secretary||May 2012||
Mr Webse has over 28 years company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services.
|Dr Geoffrey E.D Brooke||Non-Executive DirectorNon-Executive Chairman||May 2019||
Dr Brooke co-founded GBS Venture Partners in 1996 and has more than 30 years' venture capital experience. He was formerly President of Medvest Inc., a US-based earlystage venture capital group he founded with Johnson & Johnson. Dr Brooke's experience includes company formation and acquisitions as well as public listings on NYSE, NASDAQ and ASX exchanges. He is a non-executive director of Acrux Limited (ASX: ACR) and Chairman of Actinogen Medical Limited (ASX: ACW) and has been a founder, executive and director of private and public companies. From 2009 until 2015, Dr Brooke was an independent director of the Victoria WorkCover Authority.
|Dr Stewart James Washer||Non-Executive Director||Aug 2013||
Dr Washer has over 30 years of CEO and board experience in medical technology and biotech companies. He is currently the Chairman of Emyria Limited (ASX: EMD), Orthocell Ltd (ASX: OCC) and a Director of Botanix Pharmaceuticals Ltd (ASX: BOT). Dr Washer was previously a Director of AusBiotech and a Senator with Murdoch University
|Dr Darryl Maher||Non-Executive Director||Jun 2020||
Dr Maher adds global biopharmaceutical and commercialisation capability to the Cynata board, with over 23 years' experience with CSL Limited. CSL is one of the world's most successful developers of biologic pharmaceutical products and has a market capitalisation of Aus $130 billion. Dr Maher has had a long successful career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of multiple successful drug products from initiation through to clinical development and ultimately to commercialisation. Dr Maher undertook medical training, qualified as a specialist haematologist and completed a PhD before commencing his career in the pharmaceutical industry.
|Kilian Kelly||Chief Operating Officer||
|Suzanne Lipe||Vice President Partner Engagement||
|HSBC Custody Nominees (Australia) Limited||15,855,298||11.07%|
|Phillip Asset Management Limited <Bioscience MTF1 A/C>||14,285,715||9.97%|
|BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||4,978,644||3.47%|
|Citicorp Nominees Pty Limited||3,487,586||2.43%|
|BNP Paribas Nominees Pty Ltd Six SIS Ltd<DRP A/C>||3,460,179||2.42%|
|John W King Nominees Pty Ltd||2,323,596||1.62%|
|Mal Washer Nominees Pty Ltd <Mal Washer Family A/C>||2,020,000||1.41%|
|Dr Ross Alexander Macdonald||2,000,000||1.40%|
|BNP Paribas Nominees Pty Ltd Acf Clearstream||1,823,294||1.27%|
|National Nominees Pty Ltd||1,578,854||1.10%|
|Helium Management Pty Ltd <Helium S/F A/C>||1,220,366||0.85%|
|Dr Maksym Vodyanyk||1,191,658||0.83%|
|Mr Jon Nicolai Bjarnason & Mrs Rina Eghoje Bjarnason <Jarck Super Fund A/C>||1,050,000||0.73%|
|Riversdale Capital Funding Pty Ltd <The RCF A/C>||811,621||0.57%|
|Ms Kyoko Yukawa||800,000||0.56%|
|Mr Patrick Anthony Walsh||712,624||0.50%|
|CM Cook Superannuation Pty Ltd <CM Cook Super Fund A/C>||700,000||0.49%|
|Crosswind Trustee Company Limited <>Crosswind A/C>||700,000||0.49%|
|BNP Paribas Noms Pty Ltd <Drp>||683,019||0.48%|